Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1 OH midazolam in morbidly obese and weight loss surgery patients
This study aimed to describe the pharmacokinetics of midazolam and its cytochrome P450 3A (CYP3A) mediated metabolite 1 OH midazolam in morbidly obese patients receiving oral and i.v. midazolam before (n 20) and one year after weight loss surgery (n 18) thereby providing insight into the influence of weight loss surgery on CYP3A activity in the gut wall and liver. In a semiphysiologically based pharmacokinetic (semi PBPK) model in which different blood flow scenarios were evaluated, intrinsic hepatic clearance of midazolam (CLint,H) was 2 (95% CI 1.40 1.64) times higher compared to morbidly obese patients before surgery (P 0.01) Midazolam gut wall clearance (CLint,G) was slightly lower in patients after surgery (P 0.05) with low values for both groups. The results of the semi PBPK model suggest that, in patients after weight loss surgery, CYP3A hepatic metabolizing capacity seems to recover compared to morbidly obese patients, whereas CYP3A mediated CLint,G was low for both populations and showed large interindividual variability.
CPT: pharmacometrics systems pharmacology